



**ASX Announcement**  
**10 July 2023**

## **OPTISCAN TO PRESENT AT KEY INTERNATIONAL CONGRESSES IN JULY**

**Optiscan Imaging Limited (ASX: OIL)** is pleased to announce that CEO and Managing Director Dr Camile Farah has been invited to present at two prestigious international conferences in July. Dr. Farah will be speaking at the 11th International Conference of the American Head and Neck Society (AHNS) in Montreal, Canada, from 8 to 12 July, as well as the 48th Brazilian Congress of Stomatology and Oral Pathology (SOBEP) in Curitiba, Brazil, from 25 to 28 July respectively.

By special invitation, Dr Farah's first presentation, titled "Image Guided Oral Diagnosis Using Confocal Laser Endomicroscopy," will be delivered to an delegation of 1500 leading head and neck surgeons at AHNS 2023 in Montreal on 11 July. As a keynote speaker at SOBEP 2023, and among a select group of eight international lecturers, Dr Farah will present on "Real-Time Optical Microscopy of Oral Mucosal Lesions using Confocal Laser Endomicroscopy" to an audience of more than 1,000 dentists and oral physicians and pathologists, predominantly from South America. Both lectures and presentations are poised to showcase the groundbreaking advancements offered by Optiscan's real-time slide-free, biopsy-free confocal digital microscope technology.

Dr Camile Farah stated, "I am grateful to be invited to present to a plethora of leading clinical audiences across the Americas in July. The potential of our unique and cutting-edge imaging technology for head and neck surgeons and oral physicians and pathologists is significant. I am looking forward to connecting with delegates across both continents and gaining further insights and understanding of their needs in refinement of our US commercial hub and expected launch of our InVivage® intra-oral digital microscope in 2024. The meetings are also an excellent opportunity to highlight recent developments telepathology and machine learning, and to discuss potential collaborations and partnerships aimed to advance the purposes of the Company."

This announcement has been authorised for release by the Board of Optiscan.

– ends –

This announcement has been authorised for release by the Board of Optiscan.

### **For investor queries, please contact:**

Dr. Camile Farah

Chief Executive Officer & Managing Director – Optiscan Imaging Ltd

**E:** [cfarah@optiscan.com](mailto:cfarah@optiscan.com)

**P:** (61 3) 9538 3333

**A:** 16 Miles St, Mulgrave VIC 3170, Australia

**W:** [www.optiscan.com](http://www.optiscan.com)

## About Optiscan

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

## Disclaimer

*All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.*

**P:** (61 3) 9538 3333

**A:** 16 Miles St, Mulgrave VIC 3170, Australia

**W:** [www.optiscan.com](http://www.optiscan.com)